Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
Ended Project Grant Awarded Last action
- Award ID
- R44AG073141
- Recipient
-
Allied Innovative Systems UEI SFFKG8THUH55
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,493,330
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- New Jersey, USA
Award details come from USAspending.gov.
Description
- Abstract
- The long-term objective of this proposal is to further develop a photochemical signal amplification method (psam) for increasing the sensitivity of conventional enzyme-linked immunosorbent assays (elisa) for determination of biomarkers for various neurodegenerative diseases, such as alzheimer's disease (ad). Immunoenzymatic methods such as elisa are widely used in biology and medicine for drug screening, for detecting viruses (including coronaviruses), bacteria, and biomarkers, particularly cytokines and interleukins for cancer and immunological disorders, and biomarkers for neurodegenerative diseases. They are routinely used in manual, semi-automated, and automated systems where high volumes of tests are performed. However, in many cases the sensitivity of elisa is inadequate. Some of the key biomarkers for early diagnosis of ad include three cerebrospinal fluid (CSF) biomarkers: amyloid SS-42 (ASS-42), which causes formation of oligomeric plaques, total TAU (t-TAU), and phosphorylated TAU (p-TAU) (which increases intracellular neurofibrillary tangles (nfts). To date, there is no sensitive and cost- effective method for the quantification of these three proteins, hindering the diagnosis and progression monitoring of ad. Existing highly sensitive methods are cumbersome and expensive. Therefore, there is an increased necessity for a common elisa platform to detect low levels of ASS-42, t-TAU, p-TAU and other biomarkers for various neurodegenerative diseases that is both inexpensive and simple enough to not require specialized laboratory equipment. In our phase II project, we propose to further develop a very sensitive and inexpensive immunoassay platform for detection of biomarkers for various neurodegenerative diseases. In particular, we will 1) design and manufacture a pre-production psam illumination device; 2) design and develop a psam detection system kit, elisa + psam kits for detection of ASS-42, t-TAU, p-TAU, bdnf and probdnf; 3) conduct extensive performance evaluation studies towards research use only applications of the psam products.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $845,968 | |
| Amendment | $845,968 | |
| Amendment | $845,968 | |
| Amendment | $977,713 | |
| Original award | $977,713 |
Quick answers
Who received award R44AG073141?
R44AG073141 was awarded to Allied Innovative Systems by National Institute on Aging (National Institutes of Health) on September 1, 2021.
How much is award R44AG073141 worth?
$4,493,330 has been obligated on R44AG073141.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award